US5571821A
(en)
*
|
1993-05-20 |
1996-11-05 |
Texas Biotechnology Corporation |
Sulfonamides and derivatives thereof that modulate the activity of endothelin
|
US5591761A
(en)
*
|
1993-05-20 |
1997-01-07 |
Texas Biotechnology Corporation |
Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
|
US5962490A
(en)
|
1987-09-25 |
1999-10-05 |
Texas Biotechnology Corporation |
Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
|
US5514691A
(en)
*
|
1993-05-20 |
1996-05-07 |
Immunopharmaceutics, Inc. |
N-(4-halo-isoxazolyl)-sulfonamides and derivatives thereof that modulate the activity of endothelin
|
US5594021A
(en)
*
|
1993-05-20 |
1997-01-14 |
Texas Biotechnology Corporation |
Thienyl-, furyl- and pyrrolyl sulfonamides and derivatives thereof that modulate the activity of endothelin
|
DE69017656T2
(de)
*
|
1989-08-30 |
1995-08-31 |
Irwin Fox |
Wegwerfoxidträger zur entfernung von schwefelwasserstoff.
|
US5736509A
(en)
*
|
1990-12-14 |
1998-04-07 |
Texas Biotechnology Corporation |
Cyclic peptide surface feature mimics of endothelin
|
US5378715A
(en)
*
|
1992-02-24 |
1995-01-03 |
Bristol-Myers Squibb Co. |
Sulfonamide endothelin antagonists
|
TW224462B
(de)
*
|
1992-02-24 |
1994-06-01 |
Squibb & Sons Inc |
|
US5514696A
(en)
*
|
1992-05-06 |
1996-05-07 |
Bristol-Myers Squibb Co. |
Phenyl sulfonamide endothelin antagonists
|
NZ247440A
(en)
*
|
1992-05-06 |
1995-04-27 |
Squibb & Sons Inc |
Phenyl sulphonamide derivatives, preparation and pharmaceutical compositions thereof
|
US5420123A
(en)
*
|
1992-12-21 |
1995-05-30 |
Bristol-Myers Squibb Company |
Dibenzodiazepine endothelin antagonists
|
US5352800A
(en)
*
|
1993-03-11 |
1994-10-04 |
Merck & Co., Inc. |
Process for the production of a novel endothelin antagonist
|
US5401745A
(en)
*
|
1993-03-19 |
1995-03-28 |
Merck & Co., Inc. |
Quinazolinones substituted with phenoxyphenylacetic acid derivatives
|
US5374638A
(en)
*
|
1993-03-19 |
1994-12-20 |
Merck & Co., Inc. |
Six membered ring fused imidazoles substituted with phenoxyphenylacetic acid derivatives used to treat asthma
|
US5420133A
(en)
*
|
1993-03-19 |
1995-05-30 |
Merck & Co., Inc. |
Quinazolinones substituted with phenoxyphenylacetic acid derivatives
|
US5767310A
(en)
*
|
1993-03-19 |
1998-06-16 |
Merck & Co., Inc. |
Phenoxyphenylacetic acid derivatives
|
US5334598A
(en)
*
|
1993-03-19 |
1994-08-02 |
Merck & Co., Inc. |
Six-membered ring fused imidazoles substituted with phenoxyphenylacetic acid derivatives
|
EP0626174A3
(de)
|
1993-04-21 |
1996-01-03 |
Takeda Chemical Industries Ltd |
Verfahren und Zusammensetzung für die Prophylaxe und/oder Behandlung von Organunterfunktion.
|
US6030991A
(en)
*
|
1993-05-20 |
2000-02-29 |
Texas Biotechnology Corp. |
Benzenesulfonamides and the use thereof to modulate the activity of endothelin
|
US6342610B2
(en)
|
1993-05-20 |
2002-01-29 |
Texas Biotechnology Corp. |
N-aryl thienyl-, furyl-, and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
|
US6541498B2
(en)
|
1993-05-20 |
2003-04-01 |
Texas Biotechnology |
Benzenesulfonamides and the use thereof to modulate the activity of endothelin
|
US6376523B1
(en)
|
1994-05-20 |
2002-04-23 |
Texas Biotechnology Corporation |
Benzenesulfonamides and the use thereof to modulate the activity of endothelin
|
US6613804B2
(en)
|
1993-05-20 |
2003-09-02 |
Encysive Pharmaceuticals, Inc. |
Biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
|
US6087324A
(en)
|
1993-06-24 |
2000-07-11 |
Takeda Chemical Industries, Ltd. |
Sustained-release preparation
|
TW394761B
(en)
|
1993-06-28 |
2000-06-21 |
Hoffmann La Roche |
Novel Sulfonylamino Pyrimidines
|
DK0634175T3
(da)
*
|
1993-07-15 |
2001-04-30 |
Hoffmann La Roche |
Farmaceutisk kombination, der indeholder en hæmmer af renin-angiotensin-systemet og en endothelin-antagonist
|
US5686478A
(en)
*
|
1993-07-20 |
1997-11-11 |
Merck & Co. Inc. |
Endothelin antagonists
|
US6140325A
(en)
*
|
1993-08-19 |
2000-10-31 |
Takeda Chemical Industries, Ltd. |
Thienopyrimidine derivatives, their production and use
|
US5965732A
(en)
*
|
1993-08-30 |
1999-10-12 |
Bristol-Myers Squibb Co. |
Sulfonamide endothelin antagonists
|
EP0728145A1
(de)
*
|
1993-11-01 |
1996-08-28 |
Ciba-Geigy Japan Limited |
Endothelin rezeptor antagoniste
|
IL111959A
(en)
*
|
1993-12-17 |
2000-07-16 |
Tanabe Seiyaku Co |
N-(polysubstituted pyrimidin-4-yl) benzenesulfonamide derivatives their preparation and pharmaceutical compositions containing them
|
GB9504854D0
(en)
*
|
1994-03-31 |
1995-04-26 |
Zeneca Ltd |
Nitrogen derivatives
|
GB9409618D0
(en)
*
|
1994-05-13 |
1994-07-06 |
Zeneca Ltd |
Pyridine derivatives
|
US5612359A
(en)
*
|
1994-08-26 |
1997-03-18 |
Bristol-Myers Squibb Company |
Substituted biphenyl isoxazole sulfonamides
|
US5559135A
(en)
*
|
1994-09-14 |
1996-09-24 |
Merck & Co., Inc. |
Endothelin antagonists bearing pyridyl amides
|
US5538991A
(en)
*
|
1994-09-14 |
1996-07-23 |
Merck & Co., Inc. |
Endothelin antagonists bearing 5-membered heterocyclic amides
|
US6268369B1
(en)
|
1994-11-16 |
2001-07-31 |
Synaptic Pharmaceutical Corporation |
5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines
|
CZ151297A3
(cs)
|
1994-11-16 |
1998-07-15 |
Synaptic Pharmaceutical Corporation |
Dihydropyrimidinové sloučeniny a farmaceutické prostředky na jejich bázi
|
WO1996016963A1
(de)
*
|
1994-11-25 |
1996-06-06 |
F. Hoffmann-La Roche Ag |
Sulfonamide und deren verwendung als heilmittel
|
CA2162630C
(en)
*
|
1994-11-25 |
2007-05-01 |
Volker Breu |
Sulfonamides
|
CN1064965C
(zh)
*
|
1994-11-25 |
2001-04-25 |
弗·哈夫曼-拉罗切有限公司 |
新的磺酰胺类化合物及其作为药物的用途
|
US5837708A
(en)
*
|
1994-11-25 |
1998-11-17 |
Hoffmann-La Roche Inc. |
Sulphonamides
|
TW313568B
(de)
*
|
1994-12-20 |
1997-08-21 |
Hoffmann La Roche |
|
KR100432843B1
(ko)
*
|
1994-12-20 |
2004-10-14 |
에프. 호프만-라 로슈 아게 |
아릴-및헤트아릴-설폰아미드유도체,이들의제조방법및이들의엔도텔린길항제로서의용도
|
DE69530516T2
(de)
|
1994-12-28 |
2003-12-24 |
Kowa Co |
Pyrimidin-derivate
|
US5760038A
(en)
*
|
1995-02-06 |
1998-06-02 |
Bristol-Myers Squibb Company |
Substituted biphenyl sulfonamide endothelin antagonists
|
US5780473A
(en)
*
|
1995-02-06 |
1998-07-14 |
Bristol-Myers Squibb Company |
Substituted biphenyl sulfonamide endothelin antagonists
|
US5573762A
(en)
*
|
1995-04-24 |
1996-11-12 |
Genentech, Inc. |
Use of leukemia inhibitory factor specific antibodies and endothelin antagonists for treatment of cardiac hypertrophy
|
US5739333A
(en)
*
|
1995-05-16 |
1998-04-14 |
Tanabe Seiyaku Co., Ltd. |
Sulfonamide derivative and process for preparing the same
|
UA58494C2
(uk)
*
|
1995-06-07 |
2003-08-15 |
Зенека Лімітед |
Похідні n-гетероарилпіридинсульфонаміду, фармацевтична композиція, спосіб одержання та спосіб протидії впливам ендотеліну
|
GB9512697D0
(en)
*
|
1995-06-22 |
1995-08-23 |
Zeneca Ltd |
Heterocyclic compounds
|
DE19527568A1
(de)
|
1995-07-28 |
1997-01-30 |
Merck Patent Gmbh |
Endothelin-Rezeptor-Antagonisten
|
US5846990A
(en)
*
|
1995-07-24 |
1998-12-08 |
Bristol-Myers Squibb Co. |
Substituted biphenyl isoxazole sulfonamides
|
DE19528418A1
(de)
*
|
1995-08-02 |
1997-02-06 |
Merck Patent Gmbh |
Endothelin-Rezeptor-Antagonisten
|
DE19530032A1
(de)
*
|
1995-08-16 |
1997-02-20 |
Merck Patent Gmbh |
Endothelin-Rezeptor-Antagonisten
|
JPH09124620A
(ja)
|
1995-10-11 |
1997-05-13 |
Bristol Myers Squibb Co |
置換ビフェニルスルホンアミドエンドセリン拮抗剤
|
CZ260596A3
(en)
*
|
1995-10-12 |
1997-12-17 |
Hoffmann La Roche |
Sulfonamide derivative, process of its preparation and pharmaceutical composition containing thereof
|
US6228861B1
(en)
|
1995-11-16 |
2001-05-08 |
Synaptic Pharmaceutical Corporation |
Dihydropyrimidines and uses thereof
|
JP3087968B2
(ja)
*
|
1995-12-20 |
2000-09-18 |
山之内製薬株式会社 |
アリールエテンスルホンアミド誘導体及びその医薬組成物
|
US5977117A
(en)
|
1996-01-05 |
1999-11-02 |
Texas Biotechnology Corporation |
Substituted phenyl compounds and derivatives thereof that modulate the activity of endothelin
|
HUP0002351A3
(en)
|
1996-02-20 |
2001-10-29 |
Bristol Myers Squibb Co |
Methods for the preparation of biphenyl isoxazole sulfonamides, intermediates and process for preparing them
|
US5856507A
(en)
*
|
1997-01-21 |
1999-01-05 |
Bristol-Myers Squibb Co. |
Methods for the preparation of biphenyl isoxazole sulfonamides
|
US5958905A
(en)
|
1996-03-26 |
1999-09-28 |
Texas Biotechnology Corporation |
Phosphoramidates, phosphinic amides and related compounds and the use thereof to modulate the activity of endothelin
|
US5939446A
(en)
*
|
1996-04-09 |
1999-08-17 |
Bristol-Myers Squibb Co. |
Heteroaryl substituted phenyl isoxazole sulfonamide endothelin antagonists
|
US5804585A
(en)
|
1996-04-15 |
1998-09-08 |
Texas Biotechnology Corporation |
Thieno-pyridine sulfonamides derivatives thereof and related compounds that modulate the activity of endothelin
|
US6245773B1
(en)
|
1996-05-16 |
2001-06-12 |
Synaptic Pharmaceutical Corporation |
5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines
|
US6172066B1
(en)
|
1996-05-16 |
2001-01-09 |
Synaptic Pharmaceutical Corporation |
Dihydropyrimidines and uses thereof
|
CA2262676A1
(en)
*
|
1996-08-09 |
1998-02-19 |
Merck & Co., Inc. |
Stereoselective deoxygenation reaction
|
ZA978334B
(en)
*
|
1996-09-16 |
1999-03-16 |
Univ Dalhousie |
Use of IFG-I for the treatment of kidney disorders renal insufficiencies steriod toxicity and related indications
|
US5883254A
(en)
*
|
1996-11-08 |
1999-03-16 |
Hoffmann-La Roche Inc. |
Process for making pyrimidine derivatives
|
DE19653024A1
(de)
*
|
1996-12-19 |
1998-06-25 |
Merck Patent Gmbh |
Endothelin-Rezeptor-Antagonisten
|
HRP980001A2
(en)
*
|
1997-01-14 |
1998-10-31 |
Feng Xu |
Asymmetric conjugate addition reaction using a chiral additive
|
US5998625A
(en)
*
|
1997-01-14 |
1999-12-07 |
Merck & Co., Inc. |
Asymmetric conjugate addition reaction using a chiral additive
|
WO1998033781A1
(en)
*
|
1997-01-30 |
1998-08-06 |
Bristol-Myers Squibb Company |
Method for preventing or treating low renin hypertension by administering an endothelin antagonist
|
TW536540B
(en)
*
|
1997-01-30 |
2003-06-11 |
Bristol Myers Squibb Co |
Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
|
US5783705A
(en)
|
1997-04-28 |
1998-07-21 |
Texas Biotechnology Corporation |
Process of preparing alkali metal salys of hydrophobic sulfonamides
|
HU227183B1
(en)
|
1997-04-28 |
2010-09-28 |
Encysive Pharmaceuticals Inc |
Sulfonamide derivatives and pharmaceutical compositions containing them for the treatment of endothelin-mediated disorders
|
US6022972A
(en)
|
1997-08-08 |
2000-02-08 |
Merck & Co., Inc. |
Pyridine propanoic acid derivatives
|
US6410554B1
(en)
|
1998-03-23 |
2002-06-25 |
Merck & Co., Inc. |
Combination therapy for the treatment of benign prostatic hyperplasia
|
US6136971A
(en)
*
|
1998-07-17 |
2000-10-24 |
Roche Colorado Corporation |
Preparation of sulfonamides
|
US6680323B2
(en)
*
|
1998-12-23 |
2004-01-20 |
Synaptic Pharmaceutical Corporation |
Dihydropyrimidines and uses thereof
|
US6274585B1
(en)
|
1998-12-23 |
2001-08-14 |
Synaptic Pharmaceutical Corporation |
Dihydropyrimidines and uses thereof
|
MXPA01009362A
(es)
|
1999-03-19 |
2002-06-04 |
Squibb Bristol Myers Co |
Metodos para la preparacion de bifenil isoxazol sulfonamidas.
|
DE19916719A1
(de)
*
|
1999-04-13 |
2000-10-19 |
Basf Ag |
Neue ECE-Inhibitoren, ihre Herstellung und Verwendung
|
US7566452B1
(en)
|
1999-05-04 |
2009-07-28 |
New York University |
Cancer treatment with endothelin receptor antagonists
|
US6720322B2
(en)
*
|
1999-12-22 |
2004-04-13 |
Actelion Pharamceuticals Ltd. |
Butyne diol derivatives
|
IL149529A0
(en)
*
|
1999-12-22 |
2002-11-10 |
Actelion Pharmaceuticals Ltd |
Butyne diol derivatives
|
ES2285334T3
(es)
|
1999-12-31 |
2007-11-16 |
Encysive Pharmaceuticals, Inc |
Sulfonamidas y sus derivados como moduladores de la actividad de endotelina.
|
PT1254121E
(pt)
*
|
2000-01-25 |
2006-06-30 |
Hoffmann La Roche |
Preparacao de sulfonamidas
|
US6521632B2
(en)
|
2000-02-11 |
2003-02-18 |
Oy Juvantia Pharma Ltd |
Method for the treatment or prevention of a disease mediated by the alpha-2B-adrenoceptor
|
IL151017A0
(en)
*
|
2000-02-11 |
2003-02-12 |
Juvantia Pharma Ltd Oy |
Compounds useful for the treatment or prevention of a disease mediated by the alpha-2b-adrenoceptor
|
US6720324B2
(en)
*
|
2000-07-05 |
2004-04-13 |
Synaptic Pharmaceutical Corporation |
Selective melanin concentrating hormone-1 (MCH1) receptor antagonists and uses thereof
|
MY140724A
(en)
*
|
2000-07-21 |
2010-01-15 |
Actelion Pharmaceuticals Ltd |
Novel arylethene-sulfonamides
|
US6670362B2
(en)
|
2000-09-20 |
2003-12-30 |
Pfizer Inc. |
Pyridazine endothelin antagonists
|
US6639082B2
(en)
|
2000-10-17 |
2003-10-28 |
Bristol-Myers Squibb Company |
Methods for the preparation of biphenyl isoxazole sulfonamides
|
US8168616B1
(en)
|
2000-11-17 |
2012-05-01 |
Novartis Ag |
Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
|
MXPA03004780A
(es)
|
2000-12-18 |
2004-05-21 |
Actelion Pharmaceuticals Ltd |
Nuevas sulfamidas.
|
PL367040A1
(en)
*
|
2001-07-20 |
2005-02-21 |
Oy Juvantia Pharma Ltd |
Compounds useful for treatment or prevention of disease mediated by alpha-2b-adrenoceptor
|
FI116940B
(fi)
|
2001-07-20 |
2006-04-13 |
Juvantia Pharma Ltd Oy |
Alfa-2B-adrenoseptorivälitteisen sairauden hoitoon tai ehkäisyyn käyttökelpoiset yhdisteet
|
FR2831446B1
(fr)
*
|
2001-10-26 |
2004-03-05 |
Sanofi Synthelabo |
Utilisation de l'irbesartan pour la preparation de medicaments utiles pour la prevention ou le traitement de l'hypertension pulmonaire
|
IL163666A0
(en)
|
2002-02-22 |
2005-12-18 |
New River Pharmaceuticals Inc |
Active agent delivery systems and methods for protecting and administering active agents
|
AU2003248549B2
(en)
|
2002-05-24 |
2010-04-08 |
Millennium Pharmaceuticals, Inc. |
CCR9 inhibitors and methods of use thereof
|
GB0219660D0
(en)
|
2002-08-23 |
2002-10-02 |
Astrazeneca Ab |
Therapeutic use
|
CA2412856A1
(en)
*
|
2002-11-27 |
2004-05-27 |
Frederic Bodin |
Pharmaceutical composition for the treatment of pulmonary arterial hypertension
|
US7452896B2
(en)
|
2002-12-02 |
2008-11-18 |
Actelion Pharmaceuticals Ltd. |
Pyrimidine-sulfamides and their use as endothelian receptor antagonist
|
US20050101608A1
(en)
*
|
2003-09-24 |
2005-05-12 |
Santel Donald J. |
Iloprost in combination therapies for the treatment of pulmonary arterial hypertension
|
GB0327839D0
(en)
|
2003-12-01 |
2003-12-31 |
Novartis Ag |
Organic compounds
|
GB0403744D0
(en)
|
2004-02-20 |
2004-03-24 |
Astrazeneca Ab |
Chemical process
|
NZ586285A
(en)
|
2004-03-17 |
2011-12-22 |
Novartis Ag |
Use of aliskiren in monotherapy for treating diabetes and metabolic disorder (syndrome X)
|
JP2008507585A
(ja)
*
|
2004-07-26 |
2008-03-13 |
コセリックス インク |
微粒子製剤を用いて吸入したイロプロストによる肺高血圧症の治療
|
TW200628467A
(en)
|
2004-11-11 |
2006-08-16 |
Actelion Pharmaceuticals Ltd |
Novel sulfamides
|
JP4219399B2
(ja)
*
|
2005-05-17 |
2009-02-04 |
アクテリオン ファーマシューティカルズ リミテッド |
分散性錠剤
|
GT200600381A
(es)
|
2005-08-25 |
2007-03-28 |
|
Compuestos organicos
|
EP2292209A3
(de)
|
2005-09-12 |
2011-05-04 |
Actelion Pharmaceuticals Ltd. |
Stabile pharmazeutische Zusammensetzung enthaltend ein Pyrimidin-sulfamid
|
US7893050B2
(en)
*
|
2005-10-26 |
2011-02-22 |
Asahi Kasei Pharma Corporation |
Fasudil in combination therapies for the treatment of pulmonary arterial hypertension
|
EP2351569B1
(de)
|
2005-10-26 |
2012-08-22 |
Asahi Kasei Pharma Corporation |
Kombinationstherapie mit Fasudil zur Behandlung von pulmonaler Hypertonie
|
WO2007106494A2
(en)
*
|
2006-03-13 |
2007-09-20 |
Encysive Pharmaceuticals, Inc. |
Methods and compositions for treatment of diastolic heart failure
|
JP2009530280A
(ja)
*
|
2006-03-13 |
2009-08-27 |
エンサイシブ・ファーマシューティカルズ・インコーポレイテッド |
シタクスセンタンナトリウムの配合物
|
MX2008013034A
(es)
*
|
2006-04-13 |
2008-10-17 |
Actelion Pharmaceuticals Ltd |
Antagonistas del receptor de endotelina para etapas tempranas de fibrosis pulmonar idiopatica.
|
US20080026061A1
(en)
*
|
2006-06-22 |
2008-01-31 |
Reichwein John F |
Crystalline N-(4-chloro-3-methyl-5-isoxazolyl)-2-[2-methyl-4.5-(methylenedioxy)phenylacetyl]-thiophene-3-sulfonamide
|
JP5042311B2
(ja)
|
2006-07-20 |
2012-10-03 |
ノバルティス アーゲー |
Cetp阻害剤としてのアミノピペリジン誘導体
|
AR062501A1
(es)
*
|
2006-08-29 |
2008-11-12 |
Actelion Pharmaceuticals Ltd |
Composiciones terapeuticas
|
WO2008088727A2
(en)
|
2007-01-12 |
2008-07-24 |
Concert Pharmaceuticals, Inc. |
Endothelin receptor antagonists
|
US8080549B2
(en)
*
|
2007-01-12 |
2011-12-20 |
Concert Pharmaceuticals, Inc. |
Endothelin receptor antagonists
|
BRPI0809171A2
(pt)
*
|
2007-04-02 |
2014-09-16 |
Auspex Pharmaceuticals Inc |
"composto, composição farmacêutica, método para tratamento,prevençõ ou melhora de um ou mais , sintomas de uma desordem mediada pela endotelina em um sujeito, método de inibição de ligação d euma endotelina a um receptor eta ou etb e método para modular a atividade mediada pelo receptor de endotelina"
|
WO2008135795A2
(en)
*
|
2007-05-08 |
2008-11-13 |
Generics [Uk] Limited |
Polymorphic forms of bosentan
|
WO2009004374A1
(en)
*
|
2007-06-29 |
2009-01-08 |
Generics [Uk] Limited |
Process for introduction of hydroxyethoxy side chain in bosentan
|
MX2010001837A
(es)
|
2007-08-17 |
2010-03-10 |
Actelion Pharmaceuticals Ltd |
Derivados de 4-pirimidinasulfamida.
|
US20090069351A1
(en)
*
|
2007-09-09 |
2009-03-12 |
Protia, Llc |
Deuterium-enriched bosentan
|
US20110014291A1
(en)
*
|
2007-10-11 |
2011-01-20 |
Actavis Group Ptc Ehf |
Novel Polymorphs of Bosentan
|
CN101939303B
(zh)
*
|
2007-10-24 |
2014-06-11 |
基因里克斯(英国)有限公司 |
波生坦的晶型
|
EP2463282B1
(de)
|
2007-11-05 |
2013-08-07 |
Novartis AG |
4-Benzylamino-1-carboxyacyl-piperidin-Derivate als CETP-Inhibitoren zur Behandlung von Erkrankungen wie Hyperlipidämie oder Arteriosklerose
|
CA2707651A1
(en)
|
2007-12-03 |
2009-06-11 |
Novartis Ag |
1,2-disubstituted-4-benzylamino-pyrrolidine derivatives as cetp inhibitors useful for the treatment of diseases such as hyperli pidemia or arteriosclerosis
|
ES2376375T3
(es)
*
|
2007-12-18 |
2012-03-13 |
Dipharma Francis S.R.L. |
Procedimiento para la preparación de bosent�?n.
|
AU2009203174B2
(en)
|
2008-01-01 |
2014-01-30 |
Cipla Limited |
Method of synthesis of bosentan, its polymorphic forms and its salts
|
WO2009095933A2
(en)
*
|
2008-01-10 |
2009-08-06 |
Msn Laboratories Limited |
Improved and novel process for the preparation of bosentan
|
WO2009093127A2
(en)
*
|
2008-01-24 |
2009-07-30 |
Actavis Group Ptc Ehf |
Substantially pure and a stable crystalline form of bosentan
|
CN101939301B
(zh)
*
|
2008-02-08 |
2016-07-06 |
基因里克斯(英国)有限公司 |
用于制备波生坦的方法
|
CN101279948B
(zh)
*
|
2008-03-14 |
2010-08-11 |
苏州博鸿化工技术有限公司 |
4,6-二氯-5-(2-甲氧基苯氧基)-2,2'-二嘧啶的合成方法
|
WO2009141167A1
(en)
*
|
2008-05-23 |
2009-11-26 |
Synthon B.V. |
Bosentan salts
|
JP2011523655A
(ja)
*
|
2008-06-03 |
2011-08-18 |
フレセニウス メディカル ケア ドイッチュランド ゲーエムベーハー |
ガンマセクレターゼモジュレータを含む医薬組成物
|
WO2010012637A1
(en)
*
|
2008-08-01 |
2010-02-04 |
Inke, S.A. |
Process for the preparation of bosentan
|
WO2010015623A1
(en)
*
|
2008-08-05 |
2010-02-11 |
Farmaprojects, S. A. |
Process for the preparation of endothelin receptor antagonists
|
US20110263623A1
(en)
*
|
2008-08-12 |
2011-10-27 |
Cadila Healthcare Limited |
Process for preparation of bosentan
|
NZ593117A
(en)
*
|
2008-11-03 |
2013-03-28 |
Generics Uk Ltd |
HPLC METHOD FOR THE ANALYSIS OF BOSENTAN AND RELATED SUBSTANCES AND USE OF THESE SUBSTANCES AS REFERENCE STANDARDS AND MARKERS Chromatography mass spectrometry fragmentation
|
IT1393136B1
(it)
*
|
2009-03-11 |
2012-04-11 |
Sifa Vitor S R L |
Procedimento per la preparazione del bosentan
|
US20100256371A1
(en)
*
|
2009-04-02 |
2010-10-07 |
Glenmark |
Processes for the preparation of bosentan and its intermediates thereof
|
EP2419421A1
(de)
|
2009-04-13 |
2012-02-22 |
Sandoz AG |
Verfahren zur herstellung eines endothelrezeptorantagonisten (bosentan)
|
JP5654572B2
(ja)
|
2009-05-15 |
2015-01-14 |
ノバルティス アーゲー |
アルドステロンシンターゼ阻害剤としてのベンズオキサゾロン誘導体
|
MX2011012198A
(es)
|
2009-05-15 |
2011-12-08 |
Novartis Ag |
Aril-piridinas como inhibidoras de sintasa de aldosterona.
|
MX2011012627A
(es)
|
2009-05-28 |
2011-12-14 |
Novartis Ag |
Derivados aminobutiricos sustituidos como inhibidores de nepralisina.
|
AU2010251967B9
(en)
|
2009-05-28 |
2014-04-03 |
Novartis Ag |
Substituted aminopropionic derivatives as neprilysin inhibitors
|
WO2011024056A2
(en)
|
2009-08-27 |
2011-03-03 |
Aurobindo Pharma Limited |
An improved process for the preparation of bosentan
|
AU2010317410B9
(en)
|
2009-11-12 |
2014-10-23 |
Sun Pharmaceutical Industries Limited |
Crystalline forms of bosentan salts and processes for their preparation
|
WO2011061168A1
(en)
|
2009-11-17 |
2011-05-26 |
Novartis Ag |
Aryl-pyridine derivatives as aldosterone synthase inhibitors
|
JO2967B1
(en)
|
2009-11-20 |
2016-03-15 |
نوفارتس ايه جي |
Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
|
EP2507234B1
(de)
|
2009-11-30 |
2014-03-12 |
Novartis AG |
Imidazolderivate als aldosteron-synthasehemmer
|
EP2509594A1
(de)
|
2009-12-09 |
2012-10-17 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
Endothelin-hemmer zur behandlung von rasch progressiver glomerulonephritis
|
EP2368884A1
(de)
|
2010-03-25 |
2011-09-28 |
Laboratorios Lesvi, S.L. |
Verfahren zur Herstellung von Bosentan
|
JP5850576B2
(ja)
*
|
2010-07-06 |
2016-02-03 |
富士化学工業株式会社 |
ボセンタン固体分散体
|
EP2603497B1
(de)
|
2010-08-11 |
2018-08-08 |
Megafine Pharma (P) Ltd. |
Ein neues verfahren zur herstellung von bosentan
|
ES2714754T3
(es)
*
|
2010-10-01 |
2019-05-29 |
Zach System Spa |
Proceso para preparar monohidrato de bosentán y sus productos intermedios
|
WO2012056468A1
(en)
|
2010-10-13 |
2012-05-03 |
Matrix Laboratories Ltd |
A process for the preparation of bosentan
|
US8877815B2
(en)
|
2010-11-16 |
2014-11-04 |
Novartis Ag |
Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
|
US8673974B2
(en)
|
2010-11-16 |
2014-03-18 |
Novartis Ag |
Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
|
WO2012073135A1
(en)
|
2010-12-03 |
2012-06-07 |
Alembic Pharmaceuticals Limited |
An improved process for preparing bosentan
|
ES2386173B1
(es)
*
|
2011-01-13 |
2013-06-25 |
Urquima, S.A. |
Proceso de preparación de un antagonista del receptor de la endotelina
|
EP2696857A1
(de)
|
2011-04-11 |
2014-02-19 |
Alfred E. Tiefenbacher (GmbH & Co. KG) |
Pharmazeutische zusammensetzung mit bosentan
|
CN102796050B
(zh)
*
|
2011-05-23 |
2014-07-23 |
昂科生物医学技术(苏州)有限公司 |
一种Cdc42抑制剂及其应用
|
WO2013098577A1
(en)
|
2011-12-31 |
2013-07-04 |
Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi |
Pharmaceutical compositions of bosentan
|
US20130245259A1
(en)
|
2012-03-16 |
2013-09-19 |
Natco Pharma Limited |
Process for the preparation of bosentan monohydrate
|
ITMI20120701A1
(it)
|
2012-04-27 |
2013-10-28 |
Dipharma Francis Srl |
Procedimento per la purificazione di un composto benzensolfonammidico
|
CN104487057A
(zh)
|
2012-05-11 |
2015-04-01 |
韩诺生物制药株式会社 |
波生坦控释口服制剂
|
JP2015521594A
(ja)
|
2012-06-12 |
2015-07-30 |
カディラ ファーマシューティカルズ リミテッド |
ボセンタンの製造方法
|
EP2890694A4
(de)
|
2012-08-31 |
2015-12-30 |
Rao Davuluri Ramamohan |
4-tert-butyl-n-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy-)2-(2-pyrimidinyl)-pyrimidin-4-yl)-benzensulfonamidnatrium
|
UY35144A
(es)
|
2012-11-20 |
2014-06-30 |
Novartis Ag |
Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
|
KR102004422B1
(ko)
|
2012-12-20 |
2019-07-26 |
제일약품주식회사 |
보센탄 일수화물의 제조방법, 이에 사용되는 신규 중간체 및 이의 제조방법
|
CU24330B1
(es)
|
2013-02-14 |
2018-03-13 |
Novartis Ag |
Derivados del ácido 4-((1,1) bifenil-4-il)-3-(3-fosfonopropanamido) butanoico, activos como inhibidores de nep (endopeptidasa neutral)
|
JP6501775B2
(ja)
|
2013-07-25 |
2019-04-17 |
ノバルティス アーゲー |
心不全治療用の環状ポリペプチド
|
EA201690282A1
(ru)
|
2013-07-25 |
2016-09-30 |
Новартис Аг |
Биоконъюгаты синтетических апелиновых полипептидов
|
CN103554037B
(zh)
*
|
2013-11-08 |
2015-03-18 |
南京靖龙药物研发有限公司 |
一种波生坦代谢物羟基波生坦的制备方法
|
MA41580A
(fr)
|
2015-01-23 |
2017-11-29 |
Novartis Ag |
Conjugués d'acides gras de l'apeline synthétique présentant une demi-vie améliorée
|
ES2584534B1
(es)
|
2015-03-27 |
2017-03-13 |
Retinset, S.L. |
Formulación tópica oftálmica de bosentan
|
WO2018185516A1
(en)
|
2017-04-05 |
2018-10-11 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for treating cardiovascular toxicity induced by anti-cancer therapy
|
UY38072A
(es)
|
2018-02-07 |
2019-10-01 |
Novartis Ag |
Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
|
WO2023078463A1
(zh)
*
|
2021-11-08 |
2023-05-11 |
正大天晴药业集团股份有限公司 |
氮杂联苯类化合物及其应用
|